{Reference Type}: Journal Article
{Title}: Recent advances in treating constipation in children.
{Author}: Wolfson S;Saps M;
{Journal}: Expert Rev Gastroenterol Hepatol
{Volume}: 18
{Issue}: 7
{Year}: 2024 Jul 25
{Factor}: 4.095
{DOI}: 10.1080/17474124.2024.2383636
{Abstract}: <B>UNASSIGNED: </B>Functional constipation (FC) is a common childhood condition, diagnosed via the Rome IV criteria. Standard therapy includes lifestyle and dietary modification followed by initiation of osmotic laxative therapy. About 30% of children continue to experience symptoms related to FC despite appropriate management. New pharmacologic, surgical, and neuromodulatory therapies for FC are now available for use in adult and pediatric populations. In 2023, the first pharmacologic agent, linaclotide, obtained FDA approval for treatment of FC in children 6-17 years old.<BR><B>UNASSIGNED: </B>This article reviews current and emerging pharmacologic, surgical, and neuromodulation therapies for the management of FC in pediatric patients. Efficacy and safety data regarding each of these modalities was reviewed and discussed.<BR><B>UNASSIGNED: </B>Advancements in therapeutics available for the management of FC necessitate further investigation on safety and efficacy in pediatric populations. Careful consideration should be taken in choosing an available treatment with limited pediatric evidence as adult and pediatric FC have different underlying pathophysiology and require a different therapeutic approach. Standardization of methodology and pediatric endpoints are needed to optimize ability to compare efficacy of different treatments. We predict the future of pediatric FC management will include a personalized approach to care, resulting in improved outcomes.